Valuation: VACY AS

Market Cap 1.06B 0 107M 93.64M 86.31M 80.8M 152M 10.07B 155M 1.04B 401M 4.98B 401M 392M 17.26B P/E 2026 *
-5.02x
P/E 2027 * -35.1x
Enterprise Value 575M 0 57.9M 50.77M 46.8M 43.81M 82.16M 5.46B 83.86M 562M 218M 2.7B 217M 213M 9.36B EV / Sales 2026 *
-
EV / Sales 2027 * 2.98x
Free-Float
56.4%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
President 49 01/01/2017
Chief Executive Officer 54 01/01/2019
Director of Finance/CFO 51 03/05/2021
Director TitleAgeSince
Director/Board Member 54 -
Director/Board Member 57 -
Chairman 45 23/04/2025
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 107M
+0.33%+1.37%+63.66%+126.38% 55.63B
+0.82%+15.05%+79.52%+85.53% 52.25B
+1.36%+0.36%-14.52%-13.83% 23.07B
-1.04%+7.91%+3.91%+417.68% 22.41B
-0.18%+7.20%+31.37%-13.62% 17.32B
-1.10%+4.00%+29.97%-33.36% 15.94B
+2.89%+5.51%+25.42%+186.30% 13.77B
-3.35%+8.96%+134.32%+289.59% 13.47B
+1.31%+0.53%+27.83% - 12.43B
Average +0.10%+4.78%+42.39%+130.58% 25.14B
Weighted average by Cap. +0.26%+5.13%+48.50%+122.68%

Financials

2026 *2027 *
Net sales - 162M 0 16.3M 14.29M 13.17M 12.33M 23.12M 1.54B 23.6M 158M 61.26M 760M 61.19M 59.86M 2.63B
Net income -208M -0 -20.95M -18.37M -16.93M -15.85M -29.73M -1.98B -30.35M -204M -78.76M -977M -78.68M -76.96M -3.39B -41.58M -0 -4.19M -3.67M -3.39M -3.17M -5.95M -395M -6.07M -40.71M -15.75M -195M -15.74M -15.39M -677M
Net Debt -485M -0 -48.89M -42.87M -39.51M -36.99M -69.37M -4.61B -70.81M -475M -184M -2.28B -184M -180M -7.9B -578M -0 -58.2M -51.03M -47.04M -44.04M -82.58M -5.49B -84.29M -565M -219M -2.71B -219M -214M -9.41B
Logo VACY AS
Nykode Therapeutics ASA is a Norway-based clinical-stage biopharmaceutical platform company dedicated to the discovery and development of vaccines and immunotherapies for cancer and infectious diseases. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The Company develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The Company also has two universal COVID-19 vaccine candidates in development.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.245NOK
Average target price
5.000NOK
Spread / Average Target
+54.08%

Quarterly revenue - Rate of surprise